Free tool
FAERS Monitor: Robinul
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017558 or its brand name (Robinul, Glycopyrrolate). Reports on generic versions are filed under their own applications.
Reports
5,527
Serious
4,660
84% of reports
Hospitalization
2,342
Death reported
660
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,054
- asthma852
- wheezing719
- cough669
- pneumonia576
- drug ineffective444
- off label use374
- fatigue373
- malaise365
- chronic obstructive pulmonary disease361
- productive cough350
- chest discomfort337
- nausea336
- condition aggravated323
- therapeutic product effect incomplete317
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 14 |
| 2006 | 16 |
| 2007 | 30 |
| 2008 | 29 |
| 2009 | 46 |
| 2010 | 62 |
| 2011 | 74 |
| 2012 | 88 |
| 2013 | 70 |
| 2014 | 125 |
| 2015 | 134 |
| 2016 | 216 |
| 2017 | 428 |
| 2018 | 291 |
| 2019 | 315 |
| 2020 | 281 |
| 2021 | 444 |
| 2022 | 619 |
| 2023 | 568 |
| 2024 | 605 |
| 2025 | 669 |
| 2026 | 390 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,632 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wheezingSignal | 719 | 46.7 | 43.6 | 31,804 |
| asthmaSignal | 852 | 28.9 | 27.2 | 22,870 |
| productive coughSignal | 350 | 28.1 | 25.4 | 9,075 |
| chronic obstructive pulmonary diseaseSignal | 361 | 26.5 | 24.0 | 8,795 |
| therapeutic product effect incompleteSignal | 317 | 17.0 | 15.3 | 4,762 |
| chest discomfortSignal | 337 | 12.6 | 11.3 | 3,580 |
| coughSignal | 669 | 9.1 | 8.5 | 4,867 |
| dyspnoeaSignal | 1,054 | 7.1 | 6.7 | 5,656 |
| pneumoniaSignal | 576 | 6.8 | 6.3 | 2,872 |
| condition aggravatedSignal | 323 | 4.0 | 3.6 | 748 |
| malaiseSignal | 365 | 3.2 | 2.9 | 551 |
| fatigue | 373 | 1.8 | 1.7 | 143 |
| off label use | 374 | 1.6 | 1.5 | 93 |
| nausea | 336 | 1.6 | 1.5 | 81 |
| drug ineffective | 444 | 1.3 | 1.2 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.